United States Obesity Drugs Market by Product Type, Distribution Channel, End User 2024-2032
                     United States Obesity 
Drugs Market Research 
and Forecast Report 
2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " U n i t e d  S t a t e s  O b e s i t y  D r u g s  M a r k e t :  
I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  U n i t e d  
S t a t e s  o b e s i t y  d r u g s  m a r k e t  s i z e  i s  p r o j e c t e d  t o  e x h i b i t  a  g r o w t h  r a t e  ( C A G R )  o f  1 8 . 3 %  d u r i n g  
2 0 2 4 - 2 0 3 2 .
O b e s i t y  d r u g s ,  a l s o  k n o w n  a s  w e i g h t - l o s s  m e d i c a t i o n s ,  a r e  p h a r m a c e u t i c a l  s u b s t a n c e s  
Report d e s i g n e d  t o  a i d  i n  w e i g h t  r e d u c t i o n  f o r  i n d i v i d u a l s  s t r u g g l i n g  w i t h  o b e s i t y  o r  o v e r w e i g h t  
c o n d i t i o n s .  T h e s e  d r u g s  w o r k  t h r o u g h  v a r i o u s  m e c h a n i s m s ,  s u c h  a s  a p p e t i t e  s u p p r e s s i o n ,  
i n t e r f e r e n c e  w i t h  n u t r i e n t  a b s o r p t i o n ,  o r  i n c r e a s i n g  m e t a b o l i s m .  W h i l e  t h e y  c a n  b e  e f f e c t i v e  
Highlight and w h e n  u s e d  a l o n g s i d e  a  c o m p r e h e n s i v e  w e i g h t - l o s s  p r o g r a m  t h a t  i n c l u d e s  d i e t a r y  c h a n g e s  a n d  
e x e r c i s e ,  t h e y  a r e  n o t  a  s t a n d a l o n e  s o l u t i o n .  
O b e s i t y  d r u g s  a r e  t y p i c a l l y  p r e s c r i b e d  f o r  i n d i v i d u a l s  w i t h  a  b o d y  m a s s  i n d e x  ( B M I )  a b o v e  3 0  
Description o r  t h o s e  w i t h  a  B M I  a b o v e  2 7  w h o  h a v e  o b e s i t y - r e l a t e d  h e a l t h  i s s u e s ,  s u c h  a s  t y p e  2  d i a b e t e s  
o r  h i g h  b l o o d  p r e s s u r e .  I t  i s  e s s e n t i a l  t o  u s e  t h e s e  m e d i c a t i o n s  u n d e r  t h e  s u p e r v i s i o n  o f  a  
h e a l t h c a r e  p r o f e s s i o n a l ,  a s  t h e y  m a y  h a v e  s i d e  e f f e c t s  a n d  i n t e r a c t i o n s  w i t h  o t h e r  
m e d i c a t i o n s .  A d d i t i o n a l l y ,  l i f e s t y l e  c h a n g e s  s h o u l d  r e m a i n  t h e  c o r n e r s t o n e  o f  a n y  w e i g h t - l o s s  
e f f o r t .
R e q u e s t  f o r  a  P D F  s a m p l e  o f  t h i s  r e p o r t :  
h t t p s : / / w w w . i m a r c g r o u p . c o m / u n i t e d - s t a t e s - o b e s i t y - d r u g s - m a r k e t / r e q u e s t s a m p l e
Report Description
U n i t e d  S t a t e s  O b es i t y  D r u g s  Ma r ke t  T r en d s :
T he  i n c r e a s i n g  p r e va l e n c e  o f  o b e s i t y  i n  t h e  U n i t e d  S ta t e s  i s  a  p r i m a r y  d r i v e r .  W i th  m o r e  t h a n  o n e - t h i r d  o f  a d u l t s  c l as s i f i e d  a s  
ob e s e ,  t h e re  i s  a  g r o w i n g  n e ed  f o r  e f f e c t i v e  t r e a t me n t s  t o  co m b a t  t h i s  ep i d e m i c .  A dd i t i o n a l l y ,  g r ea t e r   a w a r e ne s s  ab o u t  t h e  
he a l t h  r i s k s  a s s o c i a t e d  w i t h  o b e s i t y  h a s  l e d  t o  i n c r ea s e d  d e ma n d  f o r  w e i g h t  ma n a g em e n t  s o l u t i o n s .  H e a l t h c a re  p r o f e ss i o n a l s  
a r e  a c t i ve l y  e d u c a t i n g  p a t i e n t s  a b ou t  t h e  be n e f i t s  o f  o b e s i t y  d r u g s  i n  c o n j u n c t i o n  w i t h  l i f e s t y l e  mo d i f i c a t i o n s .  O t h e r  t h a n  th i s ,  
sh i f t s   i n  l i f e s t y l e  a n d  d i e t a r y  p a t te r n s ,  c h a r a c t e r i z e d  b y  s e d en t a r y  be h a v i o r  a n d  t h e  c on s u mp t i o n  o f  ca l o r i e - de n s e  f oo d s ,  
co n t r i b u t e  t o  t h e  ob e s i t y  e p i d e m i c .  
A s  i nd i v i d u a l s  s t r u g g l e  t o  m a i n t a i n  h e a l t h y  w e i g h t s ,  t h e r e  i s  a  h e i g h te n e d  d e ma n d  f o r  i n t e rv e n t i on s  s u c h  a s  o b e s i t y  d r u gs  t o  
as s i s t  i n  w e i gh t  ma n a g em e n t .  B es i d e s  t h i s ,  d e s p i t e  c on c e r n s  a b o u t  h ea l t h c a re  c o s t s ,  t h e  w i l l i n g ne s s  o f  c o ns um e rs  t o  sp e n d  
on  t r e a tm e n t s  f o r  c h r on i c  c o n d i t i o n s  su c h  a s  o b e s i t y  r e ma i ns  h i gh .  W i t h  h e a l t hc a r e  ex p e n d i t u r e  co n t i n u i ng  t o  r i se ,  t he r e  i s  
s i g n i f i c an t  m a rk e t  p o t e n t i a l  f o r  o b e s i t y  d r u g s .  I n  l i n e  w i th  t h i s ,  t h e  a g i n g  p o pu l a t i o n  i n  t h e  U n i t ed  S t a t e s  i s  mo r e  s u s c e p t i b l e  
t o  o b es i t y  a n d  r e l a t e d  h ea l t h  c o m p l i ca t i o n s .  A s  t h e  p o pu l a t i o n  a g e s ,  t he r e  i s  a  g r e a t e r  n e e d  f o r  e f f ec t i v e  o b es i t y  m an a g e me n t  
s t r a t eg i e s ,  i n c l u d i n g  p h a r ma c o l o g i ca l  i n t e rv e n t i on s .
V i e w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w ww . i m a r c g ro u p . co m / u n i t e d - s ta t e s - o b e s i ty - d r u g s - m ar k e t
Breakup by Type:
• Prescript ion Drugs
• OTC Drugs
 
Breakup by Age:
• Chi ldren
• Adult
Report • Old
Segmentation
Breakup by Gender:
• Male
• Female
Breakup by Distribution Channel:
• Hospital  Pharmacy
• Retai l  Pharmacy
• Online
Breakup by Region:
• Northeast
• Midwest
Report • South
Segmentation • West
How has the United States obesity drugs market 
performed so far, and how will it perform in the coming 
years?
What are the drivers, restraints, and opportunities in 
the United States obesity drugs market?
Key What is the impact of each driver, restraint, and 
opportunity on the United States obesity drugs market?
Questions 
Answered in What is the breakup of the market based on the type?
the Report
Which is the most attractive type in the United States 
obesity drugs market?
What is the breakup of the market based on age?
Which is the most attractive age in the United States 
obesity drugs market?
What is the breakup of the market based on gender?
Which is the most attractive gender in the United 
States obesity drugs market?
Key What is the breakup of the market based on distribution 
channel?
Questions 
Which is the most attractive distribution channel in the 
Answered in United States obesity drugs market?
the Report What is the competitive structure of the United States 
obesity drugs market?
Who are the key players/companies in the United States 
obesity drugs market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    U n i t e d  S t a t e s  O b e s i t y  D r u g s  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    U n i t e d  S t a t e s  O b e s i t y  D r u g s  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    U n i t e d  S t a t e s  O b e s i t y  D r u g s  M a r k e t  -  B r e a k u p  b y  T y p e
    6 . 1     P r e s c r i p t i o n  D r u g s
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     O T C  D r u g s
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
7    U n i t e d  S t a t e s  O b e s i t y  D r u g s  M a r k e t  -  B r e a k u p  b y  A g e  
       
        7 . 1      C h i l d re n
            7 . 1 .1  O v e r v i ew
            7 . 1 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )
            7 . 1 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
      7 .2       Ad u l t
            7 . 2 .1  O v e r v i ew
            7 . 2 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )
            7 . 2 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
      7 .3       O ld
            7 . 3 .1  O v e r v i ew
            7 . 3 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )
            7 . 3 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
Table of 8     Un i ted  Sta tes  Obes i ty  Dru gs  Market  -  B reakup  by  Gender
      8 .1       M a l e
            8 . 1 .1  O v e r v i ew
Contents             8 . 1 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )            8 . 1 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
      8 .2       Fem a l e
            8 . 2 .1  O v e r v i ew
            8 . 2 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )
            8 . 2 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
9     Un i ted  Sta tes  Obes i ty  Dru gs  Market  -  B reakup  by  
D i s t r ibu t ion  Channe l
      9 .1       H o s p i t a l  P h a rm a cy
            9 . 1 .1  O v e r v i ew
            9 . 1 .2  H i s t o r i ca l  a n d  C u r ren t  M a r ke t  Tren d s  ( 2 01 8 - 2 0 2 3 )
            9 . 1 .3  M a r ke t  Fo rec a s t  ( 2 02 4 - 2 0 32 )
      9 .2       Re t a i l  Ph a rm a cy
            9 . 2 .1  O v e r v i ew
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / u n i t e d - s t a t e s - o b es i t y - d r u g s - m a r ke
t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: